Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II FOLFIRI + cetuximab in first-line metastatic RAS wild-type colorectal cancer with FcγRIIIa V/V genotype
2018-003778-29Phase 2Active
- Sponsor
- Istituto Nazionale Tumori IRCCS Fondazione Pascale
- Start
- Jan 2019
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC), sponsored by Istituto Nazionale Tumori IRCCS Fondazione Pascale. Primary endpoint: Objective response. Started Jan 2019; status: active.
02
Drugs
cetuximabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on 2018-003778-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003778-29.